Skip to content

Clinical Study on Licorice Xiexin Decoction in the Treatment of Chemotherapy-Induced Oral Mucositis in Breast Cancer

Clinical Study on Licorice Xiexin Decoction in the Treatment of Chemotherapy-Induced Oral Mucositis in Breast Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000319
Enrollment
Unknown
Registered
2026-02-09
Start date
2025-05-30
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-Induced Oral Mucositis in Breast Cancer

Interventions

Experimental Group:Licorice Xiexin Decoction oral
Control Group:Vitamin B2 oral

Sponsors

Shanghai University of Traditional Chinese Medicine Affiliated Longhua Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Primary breast tumor confirmed as malignant by core needle biopsy or surgical biopsy; 2) Meeting indications for breast cancer chemotherapy after evaluation; 3) Oral mucositis of Grade I or above [*Diagnostic grading criteria for oral ulcers refer to WHO Chemotherapy Drug Toxicity Grading Standards (NCI-CTC 3.0): Grade 0: Normal oral mucosa; Grade I: Oral mucosal erythema/pain without impaired eating; Grade II: Single ulcer >1.0cm or multiple ulcers with increased pain, tolerating semi-liquid diet; Grade III: Two ulcers >1.0cm, tolerating liquid diet only; Grade IV: Confluent ulcers with severe pain and inability to eat]; 4) Karnofsky score =60; 5) Female patients aged 18-75 (inclusive); 6) No severe organic/functional disorders or drug/food allergies; 7) Voluntary participation with signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Not meeting inclusion criteria; 2) Expected survival <6 months; 3) Severe cardiovascular, hepatic, renal, hematopoietic system diseases or mental disorders; 4) Pregnant/lactating women or those planning pregnancy; 5) Allergic constitution or multiple drug allergies; 6) Participating in other drug trials; 7) Receiving radiotherapy; 8) Oral autoimmune diseases (e.g., Behçet's disease, pemphigus), active oral infections (fungal/viral/bacterial), orthodontic treatment, or dental implants confirmed by dentists.

Design outcomes

Primary

MeasureTime frame
Oral ulcer healing time;

Secondary

MeasureTime frame
Oral ulcer healing efficacy rate;Pain score;Recurrence rate;Traditional Chinese Medicine Syndrome Scoring Scale;

Countries

China

Contacts

Public ContactLiu Sheng

Shanghai University of Traditional Chinese Medicine Affiliated Longhua Hospital

lshtcm@163.com18917763002

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Mar 14, 2026